Loading
A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors is a phase 1 interventional study registered as NCT02197169 by DNAtrix, Inc., with 37 participants enrolled, started 2014-09-11. Conditions recorded: Glioblastoma or Gliosarcoma. Interventions recorded: Single intratumoral injection of DNX-2401 and Interferon-gamma.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/